Cas:2720-67-4 Potassium O-propyl carbonodithioate manufacturer & supplier

Chemical Name:Potassium O-propyl carbonodithioate

CAS.NO:2720-67-4

Synonyms:Potassium propyl xanthogenate;Dithiocarbonic acid O-propyl ester potassium salt;Propylxanthic Acid Potassium Salt;PotassiuM Propylxanthate;Propyl potassium xanthate;Potassium O-Propyl Dithiocarbonate;n-propyldithiocarbonate,potassium salt;potassium O-n-propyl dithiocarbonate;Carbonodithioic acid, O-propyl ester, potassium salt (1:1);Potassium O-propyl carbonodithioate;CARBONIC ACID,DITHIO-,O-PROPYL ESTER,POTASSIUM SALT;Potassium O-propyl xanthate;Xanthic acid,propyl-,potassium salt;potassium O-propyldithiocarbonate;potassium n-propyl xanthate

Molecular Formula:C₄H₇KOS₂

Molecular Weight:174.326

HS Code:2930902000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:145.2ºC at 760 mmHg

Density:1.135g/cm3

Index of Refraction:1.537

PSA:66.62000

Exact Mass:173.957535

LogP:1.89540

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Potassium propyl xanthogenate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,potassium n-propyl xanthate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,potassium n-propyl xanthate Use and application,Propylxanthic Acid Potassium Salt technical grade,usp/ep/jp grade.

Related News: Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. Potassium O-propyl carbonodithioate manufacturer Both were in Siberia, and both are Chinese nationals who had recently traveled to China. Potassium O-propyl carbonodithioate supplier In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. Potassium O-propyl carbonodithioate vendor In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. Potassium O-propyl carbonodithioate factory Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.